AdAlta Ltd (ASX:1AD)'s Tim Oldham gives investors the lowdown on a pre-clinical program for the inhaled version of its AD-214 drug candidate. It comes after the clinical-stage drug development company secured a patent for the AD-214 i-body treatment from the Indian Patent Office earlier this week. Oldham says the development means the company has secured patent protection in almost all the world's major pharmaceutical markets, with a European greenlight pending.
AdAlta talks pre-clinical progress, Indian patent for AD-214
